Evidence mapPaperPMID 40789985Full record

ReviewDrugs & aging2025

Charcot foot disease: A new approach.

Michal Dubský, Robert Bém, Dominika Sojáková, Vladimira Fejfarová, Michael Hughes, Edward B Jude

Abstract readReview
In one paragraph

Review in Drugs & aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Michal DubskýDiabetes Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Robert BémDiabetes Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Dominika SojákováDiabetes Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Vladimira FejfarováDiabetes Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Michael HughesCentre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Science, School of Biological Sciences, Faculty of Biological Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
Edward B JudeDiabetes Center, Tameside and Glossop Integrated Care NHS Foundation Trust, Ashton-under-Lyne, Lancashire, UK. Edward.Jude@tgh.nhs.uk.ORCID 0000-0002-3186-4122

Funding

European Union Next-Generation EU and by the Ministry of Health of the Czech Republic NW24-09-00184National Institute for Research on Metabolic and Cardiovascular Diseases . LX22NPO5104
6 · The paper itself

Abstract

Charcot neuropathic osteoarthropathy (CNO) is a condition that develops in the presence of neuropathy, most commonly diabetes-related neuropathy. Owing to the neuropathy, microtrauma to the bones occur without the individual feeling them. With continued walking, bone inflammation, resorption, microfractures and structural changes occur in the bones, which result in irreversible deformities. Diagnosing this condition is often difficult and requires advanced imaging techniques, such as scintigraphy or magnetic resonance imaging, as X-ray changes may not be specific. Treatment of CNO includes immobilization, offloading, recalcification (supplementation of vitamin D and calcium) and in the most advanced cases, surgical treatment. This narrative review aims to synthesize the recent research and clinical implications relating to Charcot foot to help healthcare professionals to stay up-to-date in this relevant topic.

Indexed as

Arthropathy, NeurogenicDiabetic FootHumans

Identifiers

PMID40789985
PMCPMC12436485

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.